Comparing Avinger (NASDAQ:AVGR) and EndoChoice Holdings (GI)

EndoChoice Holdings (NYSE: GI) and Avinger (NASDAQ:AVGR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitabiliy, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for EndoChoice Holdings and Avinger, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EndoChoice Holdings 0 1 0 0 2.00
Avinger 0 3 2 0 2.40

Avinger has a consensus price target of $5.33, indicating a potential upside of 1,079.94%. Given Avinger’s stronger consensus rating and higher possible upside, analysts plainly believe Avinger is more favorable than EndoChoice Holdings.

Volatility & Risk

EndoChoice Holdings has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Avinger has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500.

Institutional & Insider Ownership

37.3% of EndoChoice Holdings shares are held by institutional investors. Comparatively, 61.1% of Avinger shares are held by institutional investors. 31.5% of EndoChoice Holdings shares are held by company insiders. Comparatively, 30.5% of Avinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares EndoChoice Holdings and Avinger’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
EndoChoice Holdings N/A N/A N/A ($2.67) -3.00
Avinger $18.17 million 0.59 -$47.92 million ($3.01) -0.15

EndoChoice Holdings has higher revenue, but lower earnings than Avinger. EndoChoice Holdings is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares EndoChoice Holdings and Avinger’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EndoChoice Holdings -90.67% -130.29% -60.59%
Avinger -304.43% -2,432.46% -115.58%

Summary

EndoChoice Holdings beats Avinger on 6 of the 11 factors compared between the two stocks.

EndoChoice Holdings Company Profile

EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company’s products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company’s imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company’s single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.

Avinger Company Profile

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

Receive News & Ratings for EndoChoice Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply